Immune-Onc: IO-108 by Immune Onc Therapeutics for Solid Tumor: Likelihood of Approval
IO-108 is under clinical development by Immune Onc Therapeutics and currently in Phase I for Solid Tumor.
Read full article »
Immune-Onc is a California-based biotechnology company that researches and develops immunotherapies for the treatment of cancer and solid tumors.
Read more